A Shot In The Head Of Nicotine Addiction

User Rating:  / 0
PoorBest 


Still, more than 400,000 deaths occur in the U.S. each year from smoking-related illnesses. The reason for these deaths is that smoking greatly increases the risk of getting lung cancer, heart attack, chronic lung diseases, stroke, and many other cancers. Moreover, smoking is perhaps the most preventable cause of breathing (respiratory) diseases within the USA.

?Smoking harms not just the smoker, but also family members, coworkers, and others who breathe the smoker's cigarette smoke, called secondhand smoke. Among infants up to 18 months of age, secondhand smoke is associated with as many as 300,000 cases of bronchitis and pneumonia each year. In addition, secondhand smoke from a parent's cigarette increases a child's chances for middle ear problems, causes coughing and wheezing, and worsens asthma.

A new vaccine, called NicVAX, could make it easier for smokers to quit. Of the nearly 34 million people in this country who have tried to quit smoking, only 1.2 million have actually managed to kick the habit permanently, according to the United States Centers for Disease Control and Prevention. But a new vaccine, called NicVAX, could make it easier for quitters to win.

NicVAX works by preventing nicotine from entering the brain where it normally acts as a stimulant. "An immunized tobacco user would theoretically receive no positive reinforcement from nicotine use," said Robert Naso, Ph.D., a senior vice president at Nabi Biopharmaceuticals, which developed the vaccine. Final approval for NicVAX could take several years.

Nabi Biopharmaceuticals is developing NicVAX ? (Nicotine Conjugate Vaccine) a novel and proprietary investigational vaccine to prevent and treat nicotine addiction and as an aid to smoking cessation. NicVAX is designed to cause the immune system to produce antibodies that bind to nicotine and prevent it from entering the brain. We believe that these nicotine antibodies will act like a "sponge" soaking up nicotine as it circulates in the blood stream and preventing it from reaching the brain. The positive stimulus in the brain that is normally caused by nicotine would then no longer be present.

Preclinical studies showed that vaccination with NicVAX can prevent nicotine from reaching the brain and block the effects of nicotine, including effects that can lead to addiction or can reinforce and maintain addiction.

Despite widespread knowledge of tobacco's dangerous health effects, smoking continues to pose a serious public health threat as the number of teenage smokers increases and others are unable to quit due, in large part, to tobacco's addictive properties. According to the CDC, an estimated 70 percent (32.2 million) of smokers want to quit, but only 2.5 percent (1.2 million) per year succeed in quitting permanently.

NicVAX is being developed to help the millions of patients in the U.S. and potentially billions worldwide who are addicted to tobacco products, or are at risk of becoming addicted.